Gene Therapy Deal Benchmarks in Rare Disease

Median Upfront

$285M

Range: $138M - $433M

Total Deal Value

$1.6B

Range: $912M - $2.2B

Royalty Rate

7.8% - 15.6%

Tiered up to 19.6%

Dev Milestones

$283M

Range: $170M - $396M

Model Your Deal

Market Analysis

Gene Therapy therapies in rare disease have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 gene therapy asset in rare disease is $285M, with total deal values reaching $1.6B. Development milestones average $283M, while regulatory milestones contribute $322M.

The rare disease gene therapy landscape is characterized by limited competitive intensity per indication but growing platform competition. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for gene therapy rare disease deals range from 7.8% to 15.6% at the base tier, with tiered escalation reaching 11.8%-19.6% on blockbuster sales. Commercial milestones averaging $682M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a gene therapy rare disease licensing deal?

Based on our analysis, Phase 2 gene therapy licensing deals in rare disease average $285M in upfront payments, with a range of $138M to $433M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for gene therapy rare disease transactions?

The median total deal value for Phase 2 gene therapy assets in rare disease is $1.6B, ranging from $912M to $2.2B. This includes development milestones ($283M), regulatory milestones ($322M), and commercial milestones ($682M).

What royalty rates are standard for gene therapy deals in rare disease?

Base royalty rates for gene therapy rare disease transactions range from 7.8% to 15.6%, with tiered escalations reaching 11.8%-19.6% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in gene therapy rare disease deals?

Gene Therapy rare disease deals allocate approximately 82% of total deal value to milestones. Development milestones ($283M) make up the largest share, followed by commercial milestones ($682M) and regulatory milestones ($322M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Gene Therapy Deal Benchmarks in Rare Disease

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Rare Disease

Monoclonal Antibody in Rare Disease

Gene Therapy in Oncology

Gene Therapy in Neurology

Ready to Calculate Your Deal Terms?